The company wanted to see more data on how effective three doses would be for children ages 6 months to 4
Pfizer and BioNTech said Friday they postponed their FDA application for a COVID-19 vaccine for children ages 4 and under, saying they wanted to see more data for a three-dose regimen because they believe “it may provide a higher level of protection in this age group.” “The trial in children 6 months through 4 years of age is ongoing and data on the first two ...
doses in this age group are being shared with the FDA on an ongoing basis,” they said in a statement, according to Axios. The companies’ decision led the FDA to postpone its Feb. 15 advisory panel meeting as it awaits the new data, which is expected to arrive in April. Pfizer initially submitted its request to approve the child vaccine earlier this month, though questions arose about the two-dose regime’s effectiveness.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA postpones advisory panel meeting on Pfizer Covid-19 vaccine for younger childrenThe US Food and Drug Administration is postponing an advisory panel meeting on authorizing Pfizer’s Covid-19 vaccine in children under 5.
Read more »
Pfizer Postpones Request To Give COVID Vaccines To Kids Under 5The company said it will wait until it has more data on a third dose.
Read more »
Pfizer postpones FDA request for Covid vaccine for kids under 5The company said it believes three doses 'may provide a higher level of protection in this age group.'
Read more »
FDA delays meeting on kid vaccines as Pfizer promises more dataThe companies have been testing a third shot after announcing in December that trial data showed two doses produced an insufficient immune response in toddlers.
Read more »
Pfizer pulls FDA request for COVID-19 vaccine for kids under 5The company said it believes three doses “may provide a higher level of protection in this age group.”
Read more »